CJC-1295 Side Effects Observed in Research

Reported Adverse Effects

CJC-1295 side effects documented in the Teichman 2006 ascending-dose human trial were mild. At doses of 30–125 μg/kg SC, injection-site erythema was reported in approximately 23% of participants; transient flushing and dizziness occurred in approximately 22%; headache was reported at higher dose levels. No serious adverse reactions were recorded at any dose level studied. Tolerability was best at 30–60 μg/kg.^[13]

The trial's adverse-event profile should be read in context: n=24 healthy adults, maximum 49 days duration. Long-term (>3 months) human safety data for CJC-1295 does not exist in the published literature.^[16]

• Injection-site erythema: ~23% of participants
• Transient flushing and dizziness: ~22%
• Headache: reported at higher dose levels
• Water retention: most consistently reported effect in clinical use reports
• No serious adverse reactions at any tested dose

Water Retention and Fluid-Related Effects

Fluid retention is among the most consistently reported effects in clinical use reports and small pilot trials. The mechanism is GH-stimulated sodium reabsorption in the distal nephron, which prevents pressure natriuresis and increases extracellular volume.^[8] This is a direct GH effect, not a CJC-1295–specific toxicity — it is observed across the GH-axis stimulation literature. Severity correlates with dose and is typically transient in rodent wash-out studies.

Axis Suppression: Does CJC-1295 Affect Natural GH Output?

Unlike exogenous GH, which suppresses pituitary output via negative feedback, CJC-1295 stimulates the pituitary's own production. The Ionescu and Frohman 2006 study confirmed that endogenous GH pulsatility is preserved — pulse frequency and amplitude remained intact despite tonic CJC-1295 administration.^[2] Post-study GH suppression was not reported in the Teichman 2006 28-day or 49-day follow-up periods.^[18] Long-term data (beyond three months) does not exist.

Stack-Specific Adverse Effects

The stacked CJC-1295 + ipamorelin combination amplifies GH pulse magnitude via dual-pathway stimulation. Documented downsides include more pronounced water retention and flushing than either peptide alone, along with injection-site reactions at both administration sites.^[13] No published human RCT has characterized adverse events specifically for the combined regimen; the adverse-event inference is extrapolated from single-agent data and the GH-axis physiology literature.

CNS Effects: Sleep and Stimulation

Community reports and small case series note vivid dreams and transient sleep disruption when the no-DAC form is dosed close to bedtime, attributed to the GH pulse coinciding with sleep onset. GH secretion is normally maximal during slow-wave sleep; an exogenously driven pulse at the same time may alter sleep architecture. Systematic sleep architecture studies for CJC-1295 no DAC are absent from the peer-reviewed literature; this remains an open question.

FDA Regulatory Safety Assessment